JPRN-jRCT2080220741未知2 期
A phase II study of NK105 for patients with previously treated advanced or recurrent gastric cancer.
ippon Kayaku Co., Ltd.0 个研究点开始时间: 2009年6月5日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •1. Gastric cancer confirmed by histological diagnosis or cytologic diagnosis
- •2. Failure to one prior chemotherapy regimen for gastric cancer
- •3. Adequate organ function, etc
排除标准
- •Priory treatments should not have included taxanes. etc
研究者
相似试验
未知
1 期
A phase I study of NK105 administrated weekly in patients with advanced solid malignancies.JPRN-jRCT2080221196ippon Kayaku Co., Ltd.25
已完成
2 期
Phase 2 study of BKM120 in patients with advanced esophagus cancerJPRN-UMIN000011217ational Cancer Center Hospital East41
未知
1 期
Phase I/II study of NK012Multiple myelomaJPRN-jRCT2080221611ippon Kayaku Co., Ltd.60
进行中（未招募）
1 期
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30
未知
1 期
Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophyDuchenne muscular dystrophyJPRN-jRCT2080223236IPPON SHINYAKU CO., LTD.16